Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IV Chemotherapy (Regimen 1), Chemotherapy
Maintenance Chemotherapy · 1 trial · 1 indication
Progression-free survival during maintenance therapy defined as time from randomization until disease progression or death, whatever occurs first.
| Arm | Type | Description |
|---|---|---|
| Maintenance Chemotherapy + Panitumumab | EXPERIMENTAL | Maintenance therapy: Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15 Re-induction upon progression: Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy. mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15 |
| Maintenance Chemotherapy w/o Panitumumab | EXPERIMENTAL | Maintenance therapy: Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15 Re-induction upon progression: Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy. mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15 |
| Name | Type | Description |
|---|---|---|
| Maintenance Chemotherapy | DRUG | - |
| Panitumumab (Within maintenance phase) | DRUG | - |
| mFOLFOX6 (Within re-induction phase) | DRUG | - |
| Panitumumab (Within re-induction phase) | DRUG | - |
Inclusion Criteria: * Signed written informed consent * Male or female ≥ 18 years of age * Histologically proven metastatic colorectal cancer * Molecular testing showing RAS wild-type in colorectal carcinoma cells * Life expectancy \> 12 weeks * At least one measurable lesion according to RECIST 1....
Top 20 of 77 competitors
Maintenance Chemotherapy is used for cancer, including metastatic colorectal cancer. It is an investigational small molecule therapy being studied as a maintenance treatment after initial induction therapy for patients with metastatic colorectal cancer. The drug is in Phase 2 clinical development.
Maintenance Chemotherapy is developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. Amgen is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metastatic colorectal cancer.
Maintenance Chemotherapy is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the maintenance treatment of metastatic colorectal cancer following induction therapy.
Maintenance Chemotherapy has been studied in clinical trial NCT01991873, a Phase 2 trial titled 'Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer.' This trial enrolled 387 patients in Germany and has been completed.
Yes, Maintenance Chemotherapy is also known as IV Chemotherapy (Regimen 1) and Chemotherapy. These alternative names refer to the same drug being developed by Amgen Inc. for the treatment of metastatic colorectal cancer.